1. Home
  2. XGN vs GANX Comparison

XGN vs GANX Comparison

Compare XGN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

N/A

Current Price

$4.51

Market Cap

71.2M

Sector

Health Care

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

N/A

Current Price

$1.80

Market Cap

78.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XGN
GANX
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.2M
78.2M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
XGN
GANX
Price
$4.51
$1.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
$8.86
$7.50
AVG Volume (30 Days)
384.6K
694.3K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
$8.12
N/A
Revenue Next Year
$13.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$1.41
52 Week High
$12.23
$4.34

Technical Indicators

Market Signals
Indicator
XGN
GANX
Relative Strength Index (RSI) 55.83 50.89
Support Level $2.68 $1.65
Resistance Level $5.55 $2.12
Average True Range (ATR) 0.39 0.12
MACD -0.06 0.00
Stochastic Oscillator 30.21 48.98

Price Performance

Historical Comparison
XGN
GANX

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: